Publication from Team1 & Oncoprot in Hepatology

ASS1 as a new biomarker for Unclassified HepatoCellular Adenomas

  • 30/06/2017

©F. Saltel / ASS1 immunostaining in UHCA ©F. Saltel / ASS1 immunostaining in UHCA

Argininosuccinate synthase 1 (ASS1): a marker of unclassified hepatocellular adenoma and high bleeding risk.

Elodie Henriet*, Aya Abou Hammoud*, Jean-William Dupuy, Benjamin Dartigues, Zakaria Ezzoukry, Nathalie Dugot-Senant, Thierry Leste-Lasserre, Nestor Pallares-Lupon, Macha Nikolski, Brigitte Le Bail, Jean-Frédéric Blanc, Charles Balabaud, Paulette Bioulac-Sage, Anne-Aurélie Raymond* and Frédéric Saltel*

Hepatocellular adenomas (HCA) are rare benign tumors divided into three main subgroups defined by patho-molecular features. In the case of unclassified HCA (UHCA), which are currently identified by default, a high risk of bleeding remains a clinical issue. Using an innovative methodology combining, laser capture and mass spectrometry analysis we identified a new biomarker for UHCA: argininosuccinate synthase (ASS1) which correlated with high risk of bleeding.

Published in Hepatology on June 23th, 2017.